BACKGROUND: Since the beginning of highly active antiretroviral therapy utilization, the association of renal impairment with treatment toxicity is more prevalent. Tenofovir disoproxil fumarate (TDF) side effects include renal toxicity. OBJECTIVE: To assess the incidence of renal damage in human immunodeficiency virus (HIV)-positive patients treated with TDF and to identify associated potential risk factors. SETTING: A public university tertiary 450-beds hospital in Spain. METHOD: Retrospective, longitudinal observational study that included adult HIV-1-infected patients treated with TDF. Patient´s treated with TDF from January 2010 to December 2012 were included. Patient follow-up started when initiating treatment with TDF up until either end of treatment or end of study (July 31, 2013). The estimated glomerular filtration rate was calculated using the four-variable modification of diet in renal disease. Renal toxicity was classified as moderate [estimated glomerular filtration rate (eGFR) < 60 ml/min] or severe (eGFR < 30 ml/min). The incidence rate for moderate and severe renal insufficiency was calculated as number of cases per 1000 patient-year. A univariate analysis and binary logistic regression was carried out in order to identify risk factors associated with renal toxicity by using the forward stepwise method (likelihood ratio) MAIN OUTCOME MEASURE: Incidence rate for moderate and severe renal insufficiency (RI) RESULTS: 451 patients were included in the study. The incidence rate of moderate RI was 29.2 cases per 1000 person-year (95% CI 22.1-36.3), whereas the incidence of severe RI was 2.2 cases per 1000 person-year (95% CI 0.3-4.1). Multivariate analysis confirmed an independent association with the risk of kidney damage for age (OR 1.08 95% CI 1.05-1.12), time on treatment with TDF (OR 1.16 95% CI 1.04-1.30), baseline creatinine (OR 49.80 95% CI 7.90-311.92) and treatment with NNRTIs (OR 0.45 95% CI 0.24-0.83). CONCLUSION: Mild to moderate renal failure is a frequent complication during treatment with TDF although severe renal impairment is scarce. Risk factors include age, duration of treatment with TDF, elevated baseline creatinine levels, and treatment with protease inhibitor boosted with ritonavir combinations.
BACKGROUND: Since the beginning of highly active antiretroviral therapy utilization, the association of renal impairment with treatment toxicity is more prevalent. Tenofovir disoproxil fumarate (TDF) side effects include renal toxicity. OBJECTIVE: To assess the incidence of renal damage in human immunodeficiency virus (HIV)-positivepatients treated with TDF and to identify associated potential risk factors. SETTING: A public university tertiary 450-beds hospital in Spain. METHOD: Retrospective, longitudinal observational study that included adult HIV-1-infectedpatients treated with TDF. Patient´s treated with TDF from January 2010 to December 2012 were included. Patient follow-up started when initiating treatment with TDF up until either end of treatment or end of study (July 31, 2013). The estimated glomerular filtration rate was calculated using the four-variable modification of diet in renal disease. Renal toxicity was classified as moderate [estimated glomerular filtration rate (eGFR) < 60 ml/min] or severe (eGFR < 30 ml/min). The incidence rate for moderate and severe renal insufficiency was calculated as number of cases per 1000 patient-year. A univariate analysis and binary logistic regression was carried out in order to identify risk factors associated with renal toxicity by using the forward stepwise method (likelihood ratio) MAIN OUTCOME MEASURE: Incidence rate for moderate and severe renal insufficiency (RI) RESULTS: 451 patients were included in the study. The incidence rate of moderate RI was 29.2 cases per 1000 person-year (95% CI 22.1-36.3), whereas the incidence of severe RI was 2.2 cases per 1000 person-year (95% CI 0.3-4.1). Multivariate analysis confirmed an independent association with the risk of kidney damage for age (OR 1.08 95% CI 1.05-1.12), time on treatment with TDF (OR 1.16 95% CI 1.04-1.30), baseline creatinine (OR 49.80 95% CI 7.90-311.92) and treatment with NNRTIs (OR 0.45 95% CI 0.24-0.83). CONCLUSION: Mild to moderate renal failure is a frequent complication during treatment with TDF although severe renal impairment is scarce. Risk factors include age, duration of treatment with TDF, elevated baseline creatinine levels, and treatment with protease inhibitor boosted with ritonavir combinations.
Authors: Sonia Rodríguez-Nóvoa; Pablo Labarga; Antonio D'avolio; Pablo Barreiro; Marta Albalate; Eugenia Vispo; Carmen Solera; Marco Siccardi; Stefano Bonora; Giovanni Di Perri; Vincent Soriano Journal: AIDS Date: 2010-04-24 Impact factor: 4.177
Authors: Giordano Madeddu; Paolo Bonfanti; Giuseppe V De Socio; Silvia Carradori; Carmela Grosso; Patrizia Marconi; Giovanni Penco; Elena Rosella; Sebastiano Miccolis; Sara Melzi; Maria Stella Mura; Simona Landonio; Elena Ricci; Tiziana Quirino Journal: Biomed Pharmacother Date: 2007-05-29 Impact factor: 6.529
Authors: Frank A Post; Lucy J Campbell; Lisa Hamzah; Lisa Collins; Rachael Jones; Rizwan Siwani; Leann Johnson; Martin Fisher; Stephen G Holt; Sanjay Bhagani; Andrew H Frankel; Edmund Wilkins; Jonathan G Ainsworth; Nick Larbalestier; Derek C Macallan; Debasish Banerjee; Guy Baily; Raj C Thuraisingham; Paul Donohoe; Bruce M Hendry; Rachel M Hilton; Simon G Edwards; Robert Hangartner; Alexander J Howie; John O Connolly; Philippa J Easterbrook Journal: Clin Infect Dis Date: 2008-04-15 Impact factor: 9.079
Authors: María Teresa Martín; Elena del Cacho; Ester López; Carles Codina; Montserrat Tuset; Elisa de Lazzari; Josep M Miró; Josep M Gatell; Josep Ribas Journal: Med Clin (Barc) Date: 2007-06-23 Impact factor: 1.725
Authors: Mark R Nelson; Christine Katlama; Julio S Montaner; David A Cooper; Brian Gazzard; Bonaventura Clotet; Adriano Lazzarin; Knud Schewe; Joep Lange; Christina Wyatt; Sue Curtis; Shan-Shan Chen; Stephen Smith; Norbert Bischofberger; James F Rooney Journal: AIDS Date: 2007-06-19 Impact factor: 4.177
Authors: Lucio Boglione; Ilaria De Benedetto; Valentina Dodaro; Marta Chiecchio; Amedeo De Nicolò; Giovanni Di Perri; Antonio D'Avolio Journal: Arch Virol Date: 2022-05-22 Impact factor: 2.574
Authors: Jihye Park; Kyu Sik Jung; Hye Won Lee; Beom Kyung Kim; Seung Up Kim; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han; Jun Yong Park Journal: Gut Liver Date: 2017-11-15 Impact factor: 4.519
Authors: Kyoung Hwa Lee; Ji Un Lee; Nam Su Ku; Su Jin Jeong; Sang Hoon Han; Jun Yong Choi; Young Goo Song; June Myung Kim Journal: Yonsei Med J Date: 2017-07 Impact factor: 2.759
Authors: Rachel A Murphy; Reagan M Stafford; Brooke A Petrasovits; Megann A Boone; Monica A Valentovic Journal: Int J Mol Sci Date: 2017-03-01 Impact factor: 5.923
Authors: Herry Mapesi; Aneth V Kalinjuma; Alphonce Ngerecha; Fabian Franzeck; Christoph Hatz; Marcel Tanner; Michael Mayr; Hansjakob Furrer; Manuel Battegay; Emilio Letang; Maja Weisser; Tracy R Glass Journal: Open Forum Infect Dis Date: 2018-04-06 Impact factor: 3.835